Premium
The reversion effect of the RNAi‐silencing mdr1 gene on multidrug resistance of the leukemia cell HT9
Author(s) -
Shao ShuLi,
Sun YingYu,
Li XuYan,
Zhang WeiWei,
Fu Bo,
Yun DongZe,
Zuo MingXue
Publication year - 2008
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1016/j.cellbi.2008.03.021
Subject(s) - small hairpin rna , rna interference , multiple drug resistance , gene silencing , reversion , transfection , biology , plasmid , k562 cells , microbiology and biotechnology , leukemia , gene , cancer research , drug resistance , rna , genetics , phenotype
Overexpression of P‐glycoprotein (P‐gp), the mdr1 gene product, confers multidrug resistance (MDR) to tumor cells and often limits the efficacy of chemotherapy. This study evaluated RNAi for specific silencing of the mdr1 gene and reversion of multidrug resistance. Three different short hairpin RNAs (shRNAs) were designed and constructed in a pSilencer 3.1‐H1 neo plasmid. The shRNA recombinant plasmids were transfected into HT9 leukemia cells. The RNAi effect was evaluated by real‐time PCR, Western blotting and cell cytotoxicity assay. In the cell, shRNAs can specifically down‐regulate the expression of mdr1, mRNA and P‐gp. Resistance against harringtonine, doxorubicin and curcumin was decreased. The study indicated that shRNA recombinant plasmids could modulate MDR in vitro .